Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients.
Tengfei GuJie LiTing ChenQingfeng ZhuJiafeng DingPublished in: International urology and nephrology (2023)
CTC count ≥ 5 at M2 exhibits excellent prognostic value for abiraterone plus prednisone therapy in mCRPC patients.